Tenofovir DF

Caitlin Soto, PharmD, BCIDP, Fidelia Bernice, Pharm.D., BCIDP
Pediatric Dosing Author: Bethany Sharpless Chalk, Pharm.D., BCPPS

INDICATIONS

FDA

  1. Treatment of HIV infection in adults and pediatric patients (≥2 years of age, weighing ≥10 kg) in combination with other antiretroviral drugs.
  2. Treatment of chronic HBV in adults and children ≥2 years of age and weighing ≥10 kg
  3. HIV pre-exposure prophylaxis (PrEP) for at-risk adults and adolescents weighing ≥35 kg (in combination with emtricitabine as Truvada [FTC/TDF])

NON-FDA APPROVED USES

  • Prevention of perinatal HBV transmission in eligible pregnant patients in conjunction with appropriate infant immunoprophylaxis
  • HIV post-exposure prophylaxis (PEP)

There's more to see -- the rest of this topic is available only to subscribers.

Last updated: November 2, 2026